Geneva, Switzerland, March 7, 2022 – Therapeutic Addex (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering the discovery and development of drugs based on allosteric modulation, announced today that it will report its full year 2021 financial results on Thursday. March 10, 2022. Tim Dyer, CEO, Roger Mills, CMO and Robert Lütjens, Head of Discovery Biology, will provide an update on the business and review its pipeline during an investor call and webcast, analysts and media at 4:00 p.m. CET (3:00 p.m. GMT / 10:00 a.m. EST / 7:00 a.m. PST) the same day.
Title: Addex Therapeutics to Announce Full-Year 2021 Financial Results and Provide Corporate Update Date: March 10, 2022
Time: 4:00 p.m. CET (3:00 p.m. GMT / 10:00 a.m. EST / 7:00 a.m. PST)
Join the conference call:
1: Within 10 minutes of the call start time, call the participant’s telephone number.
2: Provide the operator with the Participation Confirmation Coded: 5484873
About Addex Therapeutics:
Addex Therapeutic is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of new, orally available, small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional “orthosteric” small molecules or biologic drugs. Addex’s allosteric modulator drug discovery platform targets receptors and other proteins known to be essential for therapeutic intervention. Addex’s lead drug candidate, dipraglurant (negative allosteric modulator mGlu5 or NAM), is in pivotal registrational clinical trial for levodopa-induced dyskinesia in Parkinson’s disease (PD-LID) and entered a phase 2 clinical study for the treatment of blepharospasm, a form of dystonia. Addex’s third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is in a phase 2a proof-of-concept clinical trial for the treatment of epilepsy. Indivior PLC has licensed Addex’s GABAB PAM program for the development of addiction-focused drug candidates. Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. Addex shares are listed on the SIX Swiss Exchange and the American Depositary Shares representing its shares are listed on the NASDAQ Capital Market and trade under the symbol “ADXN” on each stock exchange.
Addex Forward-looking statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including with respect to the planned initiation of clinical trials. The words “may”, “will”, “could”, “should”, “should”, “expect”, “plan”, “anticipate”, “intend”, “believe”, ” estimate”, “predict”, “project”, “potential”, “continuing”, “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. All forward-looking statements contained in this press release are based on management’s current expectations and beliefs and are subject to a number of important risks, uncertainties and factors that may cause actual events or results to differ. differ materially from those expressed or implied by any forward-looking statement. forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in the Company’s Annual Report on Form 20-F filed with the SEC on March 11, 2021, together with market conditions and regulatory review. All forward-looking statements contained in this press release represent the views of Addex Therapeutics only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics expressly disclaims any obligation to update forward-looking statements.
All forward-looking statements contained in this press release represent the views of Addex Therapeutics only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics expressly disclaims any obligation to update forward-looking statements, except as required by law.